What is Codetta Biosciences?
Codetta Bio specializes in multi-omics technology for precision medicine, offering a platform that integrates the analysis of proteins, DNA, and RNA in a single workflow. Their flagship product, the Codetta Bio Concerto System, utilizes advanced techniques such as digital PCR and qPCR to deliver high-sensitivity and high-throughput biomarker measurements. The company targets various sectors including vaccine development, oncology, and gene therapy, aiming to redefine capabilities in translational research and clinical markets. With a focus on innovation and precision, Codetta Bio seeks to harmonize scientific data to facilitate breakthroughs in healthcare.
How much funding has Codetta Biosciences raised?
Codetta Biosciences has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2022): $15M with participation from Anzu Partners, Genoa Ventures, and Vc23
Key Investors in Codetta Biosciences
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors. They provide strategic support and business development expertise to help innovative companies accelerate growth and deliver long-term value.
Genoa Ventures
Genoa Ventures invests in early-stage companies at the intersection of biology and technology, aiming to empower category-defining businesses that transform industries. They offer strategic support to accelerate innovation in bioconvergence.
Vc23
VC23 Ventures is a life sciences-focused venture fund investing in next-generation biotools, diagnostics, and healthtech. They provide capital and expertise to accelerate the growth of portfolio companies, with a focus on the Biotools sector.
What's next for Codetta Biosciences?
With this substantial enterprise-level backing, Codetta Biosciences is poised to accelerate its growth and expand its market reach. The strategic investment signals a strong belief in the company's potential to revolutionize precision medicine through its integrated multi-omics analysis platform. Future endeavors will likely focus on scaling operations, further developing its Concerto System, and forging deeper partnerships within the oncology, vaccine development, and gene therapy sectors. This capital infusion is expected to drive innovation and solidify Codetta Bio's position as a leader in advanced biomarker measurement and translational research.
See full Codetta Biosciences company page
